白质的长度变化,高强度体积在患有唐氏综合征的成年人中,在阿尔茨海默氏症连续性中加速
Patrick Lao1,2, Natalie Edwards1,2,3, Lisi Flores-Aguilar4
1Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York City, New York, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|September 15, 2025
概括
白质过强度 (WMH) 在患有唐氏综合征 (DS) 和阿尔茨海默病 (AD) 的成年人中加速. 后部WMH在从轻度认知障碍发展为AD的个体中增长最快.
科学领域:
- 神经学 神经学
- 神经成像是一种神经成像.
- 唐氏综合征研究 唐氏综合征研究
背景情况:
- 在阿尔茨海默氏病 (AD) 连续期内,脑血管疾病在患有唐氏综合征 (DS) 的成年人中很常见.
- 患有DS的个体中脑血管疾病的区域变化尚不清楚.
研究的目的:
- 为了研究白质高强度 (WMH) 容量的纵向变化,在成年人DS.
- 为了确定WMH进展是否在认知状态和AD进展之间有所不同.
主要方法:
- 在阿尔茨海默氏症生物标志物联盟-唐氏综合征 (ABC-DS) 研究中利用了187名参与者的MRI扫描.
- 量化白质超强度 (WMH) 量和评估的年化变化.
- 将参与者分为认知组:认知稳定 (CS),轻度认知障碍 (MCI) -DS和AD,跟踪进展或稳定.
主要成果:
- 随着时间的推移,WMH体积发生了变化,在认知稳定组下降,在高级AD组增加.
- 在更先进的认知衰退 (MCI-DS到AD,AD) 个体中观察到更快的WMH变化,特别是在后部区域.
- 在渐进性诊断组中,WMH的单调增加表明随着时间的推移,WMH的加速.
结论:
- 后白质过强度 (WMH) 在患有唐氏综合征 (DS) 的成年人中随着阿尔茨海默病 (AD) 的进展而加速.
- 这种加速从轻度认知障碍 (MCI) -DS到AD的进展阶段开始显而易见.
更多相关视频
09:06Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease
Published on: June 9, 2018
12.6K
12:50Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
Published on: April 14, 2014
40.8K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
825
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
825
